# Nanoform Finland Oyj > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/nanoformfinland). ## Overview Nanoform Finland is a Finnish company specializing in nanotechnology and pharmaceutical particle engineering services. The company operates in the global pharmaceutical industry, providing expert services to enhance the bioavailability of active pharmaceutical ingredients (APIs). Nanoform's technology platform aims to address the low bioavailability of APIs, which is a significant barrier to drug approval. The company collaborates with international pharmaceutical and biotechnology companies to develop next-generation drug formulations. ## Products & services • Nanoparticle engineering services • Pharmaceutical particle technology • GMP and non-GMP research services • Drug formulation development • Clinical trial material production - **Nanoparticle Engineering** (40%) — Services to enhance API bioavailability using nanotechnology. - **Pharmaceutical Particle Technology** (30%) — Development of drug formulations using advanced particle technology. - **GMP Research Services** (20%) — Good Manufacturing Practice compliant research services for drug development. - **Non-GMP Research Services** (10%) — Research services not requiring GMP compliance for early-stage development. - Nanoparticle engineering services - Pharmaceutical particle technology - GMP and non-GMP research services - Drug formulation development - Clinical trial material production ## Customers Nanoform's customers primarily include international pharmaceutical and biotechnology companies seeking to improve drug formulations. These clients are interested in enhancing the bioavailability of their APIs to increase the likelihood of regulatory approval. The company also serves contract research organizations that require specialized nanotechnology expertise for clinical trials. Nanoform's services are particularly valuable for companies developing treatments for conditions with low drug absorption rates. - **Pharmaceutical Companies** (primary) — Purchase nanoparticle engineering services to improve drug formulations. - **Biotechnology Firms** (secondary) — Use particle technology to enhance bioavailability of APIs. - **Contract Research Organizations** (emerging) — Require GMP and non-GMP services for clinical trials. - International pharmaceutical companies seeking improved drug formulations - Biotechnology firms aiming to enhance API bioavailability - Contract research organizations requiring nanotechnology expertise - Companies developing treatments for low absorption conditions ## Geography Nanoform is headquartered in Finland and operates globally, serving clients in the pharmaceutical and biotechnology industries. The company's production and research activities are based in Finland, where it develops and tests its nanotechnology solutions. While the company has a strong presence in the Nordic region, it collaborates with international clients, including those in North America and Europe. This geographic diversity helps Nanoform mitigate risks associated with regional market fluctuations. - Headquartered in Finland with global operations - Production and research activities based in Finland - Strong presence in the Nordic region - Collaborates with international clients in North America and Europe ## Strategy Nanoform's strategic priorities include expanding its nanotechnology platform to address the low bioavailability of APIs. The company aims to commercialize its formulations for next-generation drugs and invest in GMP-level facilities to support clinical trials. Nanoform seeks to establish partnerships with leading pharmaceutical companies to broaden its market reach. The company is also focused on enhancing its operational efficiency and cost structure to improve profitability. - **Expand Nanotechnology Platform** (medium-term) — To improve API bioavailability and increase drug approval rates. - **Commercialize Formulations** (long-term) — To generate revenue from next-generation drug formulations. - **Invest in GMP Facilities** (short-term) — To support clinical trials and ensure compliance with regulatory standards. - Expand nanotechnology platform to improve API bioavailability - Commercialize formulations for next-generation drugs - Invest in GMP-level facilities for clinical trials - Establish partnerships with leading pharmaceutical companies - Enhance operational efficiency and cost structure ## Risks Nanoform faces several business and financial risks, including the challenge of proving the efficacy of its nanotechnology solutions in a highly regulated pharmaceutical industry. The company's early-stage growth status means it may struggle with managing growth effectively. Additionally, Nanoform is exposed to currency risks due to its international operations and financial transactions in multiple currencies. The conservative nature of the pharmaceutical market poses a risk to the adoption of new technologies, which may delay commercialization efforts. - **Proving Nanotechnology Efficacy** [critical] — Regulatory requirements in the pharmaceutical industry are stringent. - **Growth Management** [high] — The company is in an early growth stage and may face operational challenges. - **Currency Risks** [medium] — International operations expose the company to currency fluctuations. - **Technology Adoption** [high] — Pharmaceutical market's conservative nature may slow down new technology adoption. - Challenge of proving nanotechnology efficacy in a regulated industry - Early-stage growth status may affect growth management - Exposure to currency risks due to international operations - Conservative pharmaceutical market may delay technology adoption ## Accounting Nanoform's financial statements are influenced by several critical accounting matters, including revenue recognition from customer contracts, which may involve multiple performance obligations. The company must carefully manage currency fluctuations due to its international transactions, affecting financial results. Nanoform's investment in GMP and non-GMP facilities requires significant capital expenditure, impacting cash flow and financial position. The company also faces challenges in estimating the fair value of its technology assets, which can affect impairment assessments. - **Revenue Recognition** - **Currency Fluctuations** - **Capital Expenditure** - **Fair Value Estimation** - Revenue recognition involves multiple performance obligations - Currency fluctuations impact financial results due to international transactions - Capital expenditure on GMP facilities affects cash flow - Estimating fair value of technology assets impacts impairment assessments --- *Last updated: 2026-08-11T04:04:54.706227+00:00*